ActoGeniX: 20 million euros round
Ghent – The Belgian biopharma start-up ActoGeniX has closed a series A financing round in the volume of a20 million. The transaction was co-led by the two renowned VC investors Life Sciences Partners and GIMV. ActoGeniX has already announced a first closing of this transaction, raising a11.5 million. The company, which was founded in summer 2006, is developing a portfolio of novel therapeutic products addressing major diseases with unmet medical need, including gastrointestinal diseases, auto-immunity, allergy and metabolic diseases. ActoGeniX’ initial focus is on inflammatory bowel diseases and its lead product AG011 has been successfully tested in a clinical trial with Crohn’s disease patients. The company’s technology provides a solution to deliver active biologicals locally in the gastrointestinal tract, leading to a direct effect on target receptors present in the gut.